
Data to be presented at SLEEP 2020 showed Eisai Inc's lemborexant (DAYVIGO) had statistically significant long-term efficacy and safety compared with placebo on sleep maintenance and onset in patients with insomnia disorder, said Margaret Moline, PhD.




























